‘New GSK’ Raises Outlook After Shingrix Hits New Heights
Vaccine Leads Growth In New Slimline Company
The company looks to be building momentum at last, with four more late-stage trial readouts expected in the second half of 2022.
The company looks to be building momentum at last, with four more late-stage trial readouts expected in the second half of 2022.